Prospective study of plasma miRNA-32-5p as a diagnostic marker for epilepsy

Study on the role of miR-32-5p in the diagnosis and treatment of epilepsy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065002

Enrollment

Unknown

Registered

2022-10-25

Start date

2022-10-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Gold Standard:1. There are two main characteristics of epilepsy: epileptiform discharges on eeg and clinical seizures of epilepsy. 2. The onset must be paroxysmal, transitory, repetitive and objective

Index test:After the participants were fully informed consent and signed the informed consent, clinical medicine in His test items, from “Clinical Research Mirna test”, issued test items. The subjects

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Chinese male or female subjects with no age requirement; 2. Patients with clinician-diagnosed epilepsy; 3. Clinicians judged that antiepileptic drug treatment was required; 4. Subjects agreed to the study protocol and signed an informed consent form after ethics committee approval; 5. Subjects were able to voluntarily go to the take site for blood collection.

Exclusion criteria

Exclusion criteria: 1. Patients with epilepsy who have other serious medical conditions; 2. Other clinical reasons deemed by the clinician to be inappropriate for patient enrollment

Design outcomes

Primary

Measure	Time frame
Plasma miRNA-32-5p;	—

Countries

China

Contacts

Public ContactLiu Jianghua

The First Affiliated Hospital of South China University

jianghua990@126.com+86 13407340909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026